PD‐L1 detection in histology specimens and matched pleural fluid cell blocks of patients with NSCLC

Analysis of programmed death ligand‐1 (PD‐L1) in tumour samples is necessary to identify candidates for anti‐PD‐L1/PD‐L1 therapy. Because PD‐L1 is evaluated by immunohistochemistry (IHC), an adequate amount of tumour tissue is a prerequisite for PD‐L1 testing. To examine whether pleural fluid might be an alternative to biopsy/resection specimens for IHC evaluation of PD‐L1 in patients with non‐small cell lung carcinoma (NSCLC), we compared PD‐L1 by IHC between histological specimens and matched pleural fluid.

[1]  B. Ghanim,et al.  Tumour cell PD-L1 expression is prognostic in patients with malignant pleural effusion: the impact of C-reactive protein and immune-checkpoint inhibition , 2020, Scientific Reports.

[2]  M. Nead,et al.  Comparison of programmed death-ligand 1 (PD-L1) immunostain for nonsmall cell lung carcinoma between paired cytological and surgical specimens , 2018, CytoJournal.

[3]  L. Sakr,et al.  Cytology cell blocks are suitable for immunohistochemical testing for PD-L1 in lung cancer , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  D. Costa,et al.  PD-L1 testing using the clone 22C3 pharmDx kit for selection of patients with non-small cell lung cancer to receive immune checkpoint inhibitor therapy: are cytology cell blocks a viable option? , 2018, Journal of the American Society of Cytopathology.

[5]  V. Prieto,et al.  Programmed death ligand 1 testing in non–small cell lung carcinoma cytology cell block and aspirate smear preparations , 2018, Cancer cytopathology.

[6]  J. Juco,et al.  Use of the 22C3 anti–programmed death‐ligand 1 antibody to determine programmed death‐ligand 1 expression in cytology samples obtained from non–small cell lung cancer patients , 2018, Cancer cytopathology.

[7]  J. Heymann,et al.  PD‐L1 expression in non‐small cell lung carcinoma: Comparison among cytology, small biopsy, and surgical resection specimens , 2017, Cancer cytopathology.

[8]  B. Skov,et al.  Paired Comparison of PD-L1 Expression on Cytologic and Histologic Specimens From Malignancies in the Lung Assessed With PD-L1 IHC 28-8pharmDx and PD-L1 IHC 22C3pharmDx , 2017, Applied immunohistochemistry & molecular morphology : AIMM.

[9]  M. Salido,et al.  Heterogeneity of Tumor and Immune Cell PD‐L1 Expression and Lymphocyte Counts in Surgical NSCLC Samples , 2017, Clinical lung cancer.

[10]  Carlos Barrios,et al.  Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial , 2017, The Lancet.

[11]  Y. Shentu,et al.  Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. , 2016, The New England journal of medicine.

[12]  Keunchil Park,et al.  Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial , 2016, The Lancet.

[13]  Y. Shentu,et al.  Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial , 2016, The Lancet.

[14]  H. Asamura,et al.  Reliability of Small Biopsy Samples Compared With Resected Specimens for the Determination of Programmed Death-Ligand 1 Expression in Non--Small-Cell Lung Cancer. , 2015, Clinical lung cancer.

[15]  L. Valdés,et al.  Contribution of pleural fluid analysis to the diagnosis of pleural effusion , 2015 .

[16]  H. Kohrt,et al.  Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients , 2014, Nature.

[17]  A. Mansfield,et al.  Reflections on immune checkpoint inhibition in non-small cell lung cancer. , 2014, Translational lung cancer research.

[18]  John Ruscio,et al.  Constructing Confidence Intervals for Spearman’s Rank Correlation with Ordinal Data: A Simulation Study Comparing Analytic and Bootstrap Methods , 2008 .

[19]  E. Neville,et al.  BTS guidelines for the management of malignant pleural effusions , 2003 .

[20]  C. Marquette,et al.  Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[21]  L. Valdés,et al.  [Contribution of pleural fluid analysis to the diagnosis of pleural effusion]. , 2015, Medicina clinica.

[22]  R. Herbst,et al.  Programmed death ligand-1 expression in non-small cell lung cancer , 2014, Laboratory Investigation.